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ABSTRACT 
Study Objectives: Heart failure patients with central sleep apnoea/Cheyne Stokes Respiration 
(CSA/CSR) have an impaired prognosis. Continuous positive airway pressure (CPAP) and 
adaptive servo-ventilation (ASV) as well as nocturnal oxygen (O2) are proposed treatment 
modalities of CSA/CSR. Assess whether and how different treatments of CSA/CSR affect 
cardiac function. 
Methods: Databases were searched up to December 2017 for randomised controlled trials 
(RCTs) comparing the effect of any combination of CPAP, ASV, O2 or an inactive control on 
left ventricular ejection fraction (LVEF) in patients with heart failure and CSA/CSR. A 
systematic review and network meta-analysis using multivariate random-effects meta-
regression were performed. 
Results: 24 RCTs (1289 patients) were included in the systematic review and data of 16 RCTs 
(951 patients; apnoea-hypopnoea-index (AHI) 38±3/h, LVEF 29±3%) could be pooled in a 
network meta-analysis. Compared to an inactive control, both CPAP and ASV significantly 
improved LVEF by 4.4% (95%CI 0.3-8.5%, p=0.036) and 3.8% (95%CI 0.6-7.0%, p=0.025), 
respectively, whereas O2 had no effect on LVEF (p=0.35). There was no difference in treatment 
effects on LVEF between CPAP and ASV (p=0.76). The treatment effect of positive pressure 
ventilation was larger when baseline LVEF was lower in systolic heart failure.  
Conclusion: CPAP and ASV are effective in improving LVEF in patients with heart failure 
and CSA/CSR to a clinically relevant amount, whereas nocturnal O2 is not. There is no 
difference between CPAP and ASV in the comparative beneficial effect on cardiac function.  
 
Key words: central sleep apnoea/Cheyne Stokes respiration, continuous positive airway 
pressure, adaptive servo-ventilation, nocturnal oxygen, left ventricular ejection fraction 
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BRIEF SUMMARY 
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Current knowledge: Studies assessing the effect of continuous positive airway pressure 
(CPAP), adaptive servo-ventilation (ASV) or nocturnal oxygen on left ventricular systolic 
function (LVEF) in patients with heart failure and central sleep apnoea/Cheyne Stokes 
respiration (CSA/CSR) have come to contradictory findings. There is uncertainty on both type 
and benefit from treatment for this patient population. 
Study impact: This network meta-analysis combining direct evidence from within trial 
comparisons and indirect evidence from comparisons across trials shows that both CPAP and 
ASV improve LVEF to the same extent in heart failure with CSA/CSR, and meta-regression 
has shown that treating CSA/CSR with positive pressure ventilation seems to be more 
effective in improving LVEF when systolic function is more impaired. 
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INTRODUCTION 
Central sleep apnoea (CSA) with Cheyne Stokes breathing pattern (CSR) is characterized by 
the absence of airflow and inspiratory effort followed by hyperventilation in a crescendo-
decrescendo-pattern (waxing and waning).1 CSA/CSR is present in 25-40% of patients with 
heart failure and its occurrence is an indicator of adverse prognosis.2, 3 While appropriate 
pharmacological heart failure therapy is the mainstay treatment in most patients with heart 
failure and CSA/CSR, non-pharmacological heart failure treatment methods such as cardiac 
resynchronization therapy have an additional role.4 Although positive pressure ventilation has 
been shown to effectively control CSA/CSR, there is uncertainty whether treatment of 
CSA/CSR in heart failure is beneficial in terms of quality of life, cardiac function and hard 
cardiovascular endpoints. Currently, there is a discrepancy between evidence and practice for 
the treatment of CSA/CSR in patients with heart failure. This uncertainty has recently been 
addressed by a European Respiratory Society Task Force1, which concluded that there is 
insufficient knowledge of the pathophysiological background and algorithms for treatment of 
CSA. There are two commonly used modalities of non-invasive positive pressure ventilation 
(PPV) to alleviate CSA/CSR: continuous positive airway pressure (CPAP) providing a constant 
positive pressure and adaptive servo-ventilation (ASV) providing dynamic (breath-by-breath) 
adjustment of pressure support with a back-up rate to normalize breathing patterns relative to a 
predetermined target (different algorithms in use). Specifically, ASV mitigates hyperventilation 
and associated hypocapnia by delivering pre-set minute ventilation.5 Nocturnal oxygen therapy 
(O2) is less frequently used, as it is a less target-oriented alternative to treat CSA/CSR.
5 
Despite the effectiveness of PAP to treat CSA/CSR, conclusive evidence regarding 
mortality reduction has not yet been demonstrated.6-9 The results of the SERVE-HF8 trial have 
raised the question whether the hemodynamic effects of PPV in the subgroup of patients with 
severe systolic heart failure might be disadvantageous. As a consequence of the unexplained 
increased risk of mortality in the ASV-arm in patients with systolic heart failure and CSA in 
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the SERVE-HF trial8, the recommendation was made not to start ASV in patients with a left 
ventricular ejection fraction (LVEF) <45%.4 However, underlying pathophysiological 
mechanisms and potential explanations are a shortcoming.  
To address some of these uncertainties, a systematic review on the effects of treatment 
of CSA/CSR on heart failure was performed. To increase power of data pooling and to enable 
a better comparison of different established treatment methods of CSA/CSR, a network meta-
analysis approach was used. The objective of this network meta-analysis was to compare the 
effects of three proposed treatment modalities for CSA/CSR (CPAP, ASV, O2) on cardiac 
function in heart failure patients and to answer the question whether the effects of positive 
pressure ventilation on cardiac function differ among the severity of heart failure. In view of 
the high prevalence, the current uncertainty on the prognostic role of treating CSA/CSR in heart 
failure, and the discussion initiated by the findings of the SERVE-HF trial, the questions 
addressed by this meta-analysis are important and the method applied provides the best 
available evidence. 
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METHODS 
 
Trial registration and reporting 
The network meta-analysis was registered in the PROSPERO database (PROSPERO 2016: 
CRD42016050960). The results are reported according to PRISMA guidelines.10 
 
Eligibility criteria 
Randomised controlled trials (RCTs) were eligible for inclusion into the systematic review if 
they randomly allocated adult patients (age ≥18 years) with heart failure with reduced (HFrEF), 
mid-range (HFmrEF) or preserved (HFpEF) ejection fraction, and predominantly CSA/CSR 
(apnoea-hypopnoea-index (AHI) > 5/h, >50% central events) to two of the following treatment 
groups: fixed pressure CPAP (CPAP), adaptive servo-ventilation (ASV), nocturnal oxygen 
(O2), and inactive control (standard care or a sham-device). Patients had to be followed-up for 
at least one month. LVEF was assessed by either echocardiography or radionuclide 
ventriculography. RCTs had to report LVEF at baseline and at follow-up or the treatment effect 
on LVEF. Concomitant presence of obstructive apnoeas and hypopnoeas were not defined as 
an exclusion criteria, however, sleep apnoea had to be predominantly central (CSA/CSR > 
50%). When trials included the same patients in sub-studies, only the larger of the trials was 
included. No language restriction was applied. 
 
Search strategy and trial identification 
PubMed/Medline, Embase and the Cochrane Central Register of Controlled Trials were 
searched up to December 2017 using the following search terms: (heart failure[Title]) AND 
(sleep OR cheyne[Title/Abstract]) AND (ASV OR CPAP OR BiPAP OR NIV OR oxygen OR 
pressure[Title/Abstract]) AND random*. Full texts and/or abstracts were screened to identify 
eligible trials. Trial registries (ClinicalTrials.gov, ISRCTN.com) and bibliographies of all 
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eligible RCTs were additionally screened. Two authors independently performed the literature 
search. 
 
Outcomes 
The primary outcome was the difference in change in LVEF from baseline to follow-up 
(treatment effect) between the following comparisons: 1. CPAP vs. inactive control, 2. ASV vs. 
inactive control, 3. O2 vs inactive control, 4. CPAP vs. ASV, 5. ASV vs O2. 
Secondary outcomes were the association of the treatment effect with baseline LVEF, 
baseline AHI, length of follow-up, nightly treatment usage, and number of participants in the 
trials comparing PPV to an inactive control.  
 
Data extraction 
Data were extracted independently by two authors (see appendix). 
 
Quality and bias assessment 
Quality of the included trials was independently assessed by two authors using the Cochrane 
Collaboration’s tool for assessing risk of bias.11 Funnel plots were used to visualize potential 
publication and other bias. The quality of the estimated treatment effect in the network meta-
analysis was rated using the approach of the GRADE working group considering the extent of 
the contribution of direct and indirect evidence.12, 13 
 
Statistical methods 
A network meta-analysis was performed to assess treatment effects on LVEF between different 
treatment comparisons (three different active treatments and inactive control), and multivariate 
random-effects meta-regression was used. In addition, pairwise random-effects meta-analyses 
were performed to compare findings from pooling direct evidence with the findings also 
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including indirect evidence. To account for possible between study heterogeneity, random 
effects models were used in both the pairwise (direct) and network models. Heterogeneity was 
assessed using Cochran’s χ2 test and the I2 statistic. Inconsistency was tested by design-by-
treatment-interaction models. Consistency models assuming that treatment effects estimated 
from direct and indirect comparisons are the same were also used.14 Because the interactions in 
the inconsistency models were not statistically significant, however, only results from the 
consistency models have been reported. Pooled treatment effects are shown in forest plots 
summarizing different treatment comparisons. 
Mean LVEF values and measures of their variability at baseline and at follow-up in each 
treatment arm were used to calculate treatment effects if not sufficiently reported. The mean 
correlation – computed from studies reporting the necessary data – between baseline and 
follow-up was used to calculate the standard error (SE) of the treatment effect in each study 
arm.15  
Analysis of associations between the treatment effect on LVEF and pre-specified trial 
characteristics were performed using meta-regression to investigate possible sources of 
heterogeneity. Analyses were performed using Stata version 15.0 (StataCorp, College Station, 
TX, USA). 
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RESULTS 
 
Search results 
Search strategy identified 126 records. All studies were screened for eligibility and finally, 24 
RCTs (n=1289) evaluating any combination of CPAP, ASV, O2, and inactive control (standard 
treatment or sham-device) on LVEF in patients with heart failure and CSA/CSR were eligible 
for the systematic review (figure 1, online references).  
Seven RCTs compared CPAP to an inactive control, eight RCTs compared ASV to an 
inactive control, four trials compared ASV and CPAP with each other, three studies compared 
nocturnal oxygen to an inactive control, and two RCTs compared ASV and nocturnal oxygen. 
Four trials (n=259) were sub-studies of another RCT or included the same participants as a 
previous RCT and thus were excluded from the data pool. Another four RCTs (n=79) could not 
be included in the quantitative meta-analysis because they did not report sufficient outcome 
data (table S1). Data of 16 RCTs (n=951) could be pooled in a network meta-analysis. The 
network map is shown in figure 2.  
 
Trial characteristics 
The trial characteristics are listed in table S1 and S2, and baseline characteristics separated by 
comparison groups are shown in table 1. Overall, the middle-aged overweight study population 
(n=951) had moderate to severe CSA/CSR and moderately to severely reduced LVEF (table 
S2). A comparison of baseline characteristics between different treatment comparison groups 
revealed a statistically significant difference in AHI at baseline between groups (ANOVA, p = 
0.002), whereby the study population in the trials including a CPAP-arm had more severe 
CSA/CSR at baseline (table 1). Reduction in LVEF, severity of CSA/CSR, length of follow-
up, age and BMI were comparable between treatment comparison groups (table 1). 
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Primary outcome 
Compared to an inactive control, both CPAP and ASV significantly improved LVEF by 4.4% 
(95%CI 0.3 – 8.5%, p = 0.036) and 3.8% (95%CI 0.6 – 7.0%, p = 0.025), respectively, whereas 
O2 had no statistically significant effect on LVEF (3.2% (95%CI -3.9 – 10.2%, p = 0.35)) (figure 
3). There was no difference in the treatment effect on LVEF between CPAP and ASV (-0.6% 
(95%CI -4.8 – 3.6%, p = 0.76)). Unexpectedly, there was no statistically significant difference 
in the effect on LVEF between ASV and O2 (-0.6% (95%CI -7.7 – 6.4%), p = 0.846) based on 
the pooled data within the network. This was however likely due to the small amount of 
evidence comparing ASV and O2.  
There was no statistically significant design by treatment interaction observed for the 
comparison of CPAP, ASV and O2 with an inactive control (p=0.35), for the comparison 
between CPAP and ASV (p=0.18), or the comparison between O2 and ASV (p=0.78), indicating 
no inconsistency between direct and indirect evidence. The between study variance (τ2) was 
17.9. 89.8% (I2) of the variation was due to heterogeneity (Q with 13 degrees of freedom = 
107.5). 
  
General quality of evidence and bias assessment 
The funnel plot demonstrates a certain void of small negative studies (figure S1). Comparison 
of indirect and direct evidence did not show any statistically significant differences (table S3). 
A contribution matrix shows the extent to which the direct evidence contributed to the network 
estimate (figure S2). Results on bias assessment and on rating of evidence are shown in 
supplemental material (table S4 & S5, figure S3). According to the quality of evidence rating, 
the true effect of CPAP and ASV compared to inactive control lies close to that of the estimate 
of the network meta-analysis, whereas the degree of confidence in the network estimate on the 
effect of O2 versus inactive control and the comparison between two active treatments is only 
moderate. 
11 
   
Secondary outcomes 
Meta-regressions on the association of the treatment effect of PPV compared to an inactive 
control (11 RCTs) with pre-specified outcomes did not demonstrate any role of severity of heart 
failure (p=0.16) or CSA/CSR (p=0.78) and nightly treatment usage (p=0.20) (figure S4). There 
was a statistically significant negative association between the reported treatment effect and the 
sample size (p<0.001). The role of the length of follow-up was not assessed due to the narrow 
distribution of the length of follow-up. 
However, within the group of trials with a mean baseline LVEF < 45% comparing PPV 
to an inactive control (10 RCTs, exclusion of HFpEF16), there was a statistically significant 
negative association between baseline LVEF and the treatment effect on LVEF (p=0.008) 
(figure S5). 
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DISCUSSION 
The main finding of the network meta-analysis is that both CPAP and ASV improve LVEF by 
around 4% (absolute percentage) whereas nocturnal O2 has no effect on LVEF in patients with 
heart failure and CSA/CSR. There is no difference in the treatment effect on LVEF between 
CPAP and ASV in this population. The observed effect size is comparable to beta-blocker 
treatment in HFrEF.17 Findings of individual RCTs provided contradictory and sometimes 
inconclusive evidence on cardiac function, in particular for ASV and the comparison between 
CPAP and ASV. This network meta-analysis provides the most robust evidence on the effect 
of treatment of CSA/CSR on cardiac function in heart failure. It is of interest that the beneficial 
effect on systolic function was larger in trials with a lower mean LVEF in the group of patients 
with a LVEF < 45%.  
The network approach (adding indirect to the direct evidence) further narrowed the 
confidence interval of the pooled treatment effect compared to the pairwise meta-analysis, and, 
thus, improved certainty of the evidence. However, the network lowered the effect size of CPAP 
vs standard treatment in comparison to considering only direct evidence, whereas the network 
increased the effect size of ASV vs standard treatment. Despite the finding of superiority of 
ASV to CPAP in improvement of LVEF in some small RCTs directly comparing ASV to CPAP, 
neither the network meta-analysis nor the pairwise meta-analysis showed any difference in 
treatment effects on LVEF between CPAP and ASV. The quality of evidence for the effects of 
both CPAP and ASV vs inactive control is high, and the direct evidence is consistent with the 
indirect evidence. The findings on the effect of nocturnal O2 and on the comparison between 
CPAP and ASV have to be interpreted with caution because of the relatively low number of 
trials. However, the recommendation of guidelines to use nocturnal oxygen as standard 
treatment for CSA/CSR in heart failure because of beneficial effects on cardiac function, cannot 
be supported. 
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A reduced LVEF is the pathognomonic hallmark of systolic heart failure. LVEF is 
improved by PPV in CSA/CSR and it remains unclear why this does not translate into beneficial 
long-term cardiovascular outcomes. However, the findings of the two large RCTs on PPV and 
hard cardiovascular endpoints in patients with heart failure and CSA/CSR (CANPAP6, 7, 
SERVE-HF8, 9, 18) raised many questions on hemodynamic effects of PPV, differences between 
HFpEF and HFrEF, the ASV device algorithm used, the role of adherence to PAP, and on the 
implication of CSA/CSR in heart failure itself. A recent physiologic study suggested that there 
are two different types of hyperpneas in CSA/CSR characterized by end-expiratory lung 
volume, which are associated with cardiac function and potentially lead to differing 
hemodynamic effects; this finding highlights the complexity of the effects of CSA/CSR on 
cardiac function and suggests the need for physiologic assessments to address this heterogeneity 
to further guide treatment decisions.19 
Meta-regressions were performed for subgroup identification and to study the role of 
baseline LVEF, severity of CSA/CSR and treatment adherence to find potential explanations 
of the controversial findings in the literature. This analysis shows that within the group of 
patients with heart failure with reduced ejection fraction, the increase in LVEF while treated 
for CSA/CSR with PPV is larger when LVEF is more severely reduced. This unexpected 
finding in view of the SERVE-HF trial warrants further research trials. 
 
Results in the context of the literature  
Four RCTs were not entered in the quantitative network meta-analysis because they did not 
report sufficient outcome data on LVEF. The conclusions from these trials did not alter the 
findings of the network meta-analysis (table S1).  
Aggarawal et al.20 pooled data (n=301) studying the effect of CPAP on LVEF in patients 
with systolic heart failure and CSA/CSR or obstructive sleep apnoea (OSA) and found a pooled 
mean difference in LVEF of +5%. Interestingly, they found similar effects of CPAP on LVEF 
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in CSA/CSR and OSA in subgroup analyses. The effect size is comparable to our analysis and 
also to the effect of CPAP on LVEF in a meta-analysis in OSA (n=259), which found an 
increase in LVEF of 5% in OSA patients with heart failure.21 However, hemodynamic effects 
of CSA/CSR and OSA are different and make a direct comparison between these two distinct 
entities of sleep-disordered breathing difficult. Furthermore, CSR is not only a sleep-related 
breathing disorder but can also be present during wakefulness.22 However, CSA/CSR and OSA 
are both associated with an increased sympathetic activity with potentially deleterious effects 
on the failing heart. Wu et al.23 found a pooled mean difference in LVEF of +4.7% favouring 
ASV compared to CPAP, BiPAP or an inactive control (n=271) and Sharma and colleagues24 
found a minimal but statistically significant pooled mean difference in LVEF of +0.4% (n=385) 
in heart failure and sleep-disordered breathing. Overall, our findings on PPV compared to 
control are consistent with existing literature.25 However, conclusions on the comparison 
between CPAP and ASV are new. Because CPAP and ASV have only been directly compared 
in a few small studies, conventional pairwise meta-analyses may have lacked the power to 
assess the difference between these two treatment modalities. The network approach allowed 
to increase the numbers to compare ASV vs CPAP from 104 (2 trials) to 859 (13 trials) and this 
strengthened the quality of evidence that neither modality is superior. Non-randomized 
controlled trials did not confirm the findings of an adverse effect of ASV on cardiovascular 
mortality.26, 27 While meta-regression has shown that treating CSA/CSR with PPV seems to be 
more effective in improving LVEF when systolic function is more impaired, the mortality risk 
was markedly increased in the subgroup of HFrEF patients in the SERVE-HF trial allocated to 
ASV with an LVEF <30%.28 Taken together, this supports that the adverse outcome observed 
in the ASV arm of the SERFE-HF trial is likely due to arrhythmia and not due to effects on 
cardiac function. However, up to now there is no consensus on mechanistic hypotheses.28, 29 
There remains a need for large RCTs including patients with sufficient adherence to 
PPV, and the upcoming results of the ongoing ADVENT-HF trial may provide further insight 
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into the effects of ASV on cardiovascular outcomes in patients with heart failure and sleep 
disordered breathing (this trial includes patients with HFrEF and CSA/CSR and/or OSA).30  
 
Effect size in the context of long-term outcomes and other interventions 
The minimal clinically important difference in left ventricular ejection fraction or the cut off 
for responders to therapy is not well defined but has been estimated to be about 5%.31 The inter-
observer variability of LVEF estimation by echocardiography and application of e.g. the 
modified biplane Simpson’s rule to quantify LVEF is of similar size.32 Despite small effects in 
absolute percent change in LVEF (3.5-6.5% increase) in response to PPV in CSA/CSR and 
heart failure, an absolute improvement of 5% in a patient with a LVEF of 30% (mean LVEF of 
the study population was 29%) translates into a relative improvement of 17%. This effect size 
may lift the patient from the category of severely reduced LVEF to a more moderately reduced 
category, which holds a better prognosis. The effect of treating CSA/CSR is comparable to the 
effect size of pharmacotherapy33 or other interventions on LVEF in heart failure with reduced 
ejection fraction, e.g. beta-blockers 5%17, 31, cardiac resynchronization therapy 5-10%34, or 
angiotensin converting enzyme inhibitors 3%35.  
 
Limitations 
An important limitation of the sum of the included RCTs is the emphasis on patients with 
systolic heart failure and predominately moderately to severely reduced LVEF. In light of the 
recommendation not to use ASV in patients with heart failure and a LVEF < 45% in the latest 
international heart failure guidelines4, more insight into the effects of PPV across the whole 
severity spectrum of heart failure would be important. A subgroup analysis of HFpEF was not 
possible because of the limited number of RCTs in HFpEF. Besides the effect on cardiac 
function, the impact of PPV on quality of life is of importance in these patients and should be 
an integral part of decision-making. Data pooling of RCTs reporting on quality of life in 
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response to treatment of CSA/CSR is not possible because of the many different questionnaires 
used in individual trials. The observed higher cardiovascular mortality in the ASV arm in the 
SERVE-HF trial limits a direct implementation of the clinically relevant increase in cardiac 
function by PPV into a recommendation to treat patients with systolic heart failure with PPV. 
In addition, due to the lack of sufficient data on supplemental oxygen and the potential 
subjective benefits36 of this treatment, nocturnal O2 cannot be excluded as potential treatment 
in this group. 
 
Future directions 
There are ongoing randomised controlled and observational trials26, 30 using different ASV 
therapy algorithms. These studies might result in reassessment of the current treatment 
recommendations on ASV in HF. However, considering the inconsistent evidence on effects of 
treating CSA/CSR on the failing heart, the positive effect of CPAP on transplantation-free 
survival in those with suppressed CSR/CSA on CPAP7, the limited data on hard cardiovascular 
endpoints6, 8, and the paucity of data on supplemental oxygen, which is a treatment that targets 
the underlying pathophysiology (loop gain) of CSA/CSR, there is a need for future RCTs on 
different treatment modalities for CSA/CSR. RCTs that look at the effectiveness of different 
treatment modalities for CSA/CSR in responders (suppression of CSA/CSR) should be powered 
to detect an effect on hard cardiovascular endpoints and stratify patients by severity of heart 
failure before a final conclusion can be made. These trials should also include HFpEF since 
there is a signal for better outcomes on ASV in this group.26, 37 Until we have new evidence, 
ASV cannot be used to treat CSA/CSR in patients with systolic heart failure, but CPAP should 
be evaluated as treatment of choice for CSA/CSR in symptomatic patients with persisting 
CSA/CSR on optimal therapy for heart failure.1 
 
Conclusions 
17 
Both CPAP and ASV improve cardiac function in patients with heart failure and CSA/CSR to 
a clinically relevant extent, whereas nocturnal O2 does not. There is no difference in the effect 
on LVEF between CPAP and ASV. 
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ABBREVIATIONS 
AHI  apnoea-hypopnoea-index 
ANOVA analysis of variance 
ASV  adaptive servo-ventilation 
CPAP  continuous positive airway pressure 
CSA/CSR central sleep apnoea/Cheyne Stokes Respiration 
HFmEF heart failure with mid-range ejection fraction 
HFpEF heart failure with preserved ejection fraction 
HFrEF  heart failure with reduced ejection fraction 
LVEF  left ventricular ejection fraction 
O2  nocturnal oxygen 
PPV  positive pressure ventilation 
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FIGURE LEGENDS 
Figure 1. PRISMA flow. Flowchart of literature search. OSA = obstructive sleep apnoea. 
CSA/CSR = central sleep apnoea/Cheyne Stokes respiration. RCTs = randomised controlled 
trials. O2 = nocturnal oxygen. BiPAP = bi-level pressure support non-invasive ventilation. SA 
= sleep apnoea.  
 
Figure 2. Network map. Network map showing the number of trials (sample size) in which 
fixed pressure continuous positive airway pressure (cCPAP), adaptive servo-ventilation (ASV), 
nocturnal oxygen (O2) and inactive controls (IC) were compared.  
 
Figure 3. Forest plot. Forest plot showing the results of the pairwise and network meta-
analyses in each of the five comparison groups.  Box sizes are proportional to the weight of 
each study in the random-effects meta-analysis. cCPAP = fixed pressure continuous positive 
airway pressure, ASV = adaptive servo-ventilation, O2 = nocturnal oxygen, standard = inactive 
control. 
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TABLES 
Table 1: Summary of trial characteristics by type of treatment comparison 
 Weighted mean (SE)  
 
CPAP vs 
IC (n=4) 
ASV vs IC 
(n=7) 
ASV vs 
CPAP 
(n=3) 
O2 vs IC 
(n=1) 
ASV vs O2 
(n=1) 
P-value 
(ANOVA) 
Age (years) 62.8 (1.0) 68.5 (1.3) 64.3 (2.3) 64.1 68.5 0.10 
BMI (kg/m2) 28.7 (0.5) 25.3 (0.8) 26.6 (0) -- 23.8 0.31 
AHI (/h) 39.9 (0.3) 28.5 (2.4) 47.0 (2.9) 19.4 35.6 0.002 
LVEF (%) 23.9 (1.0) 33.7 (6.0) 32.7 (1.0) 33.7 35.6 0.18 
Length of follow-up 
(months) 
3 (0) 4.8 (0.9) 3 (0) 3 3 0.43 
ACE (%) 79.6 (3.0) 85.5 (5.0) 91.7 (0.6) 62.5 78.2 0.17 
Betablocker (%) 76.5 (4.1) 94.0 (3.1) 75.2 (3.8) - 84.7 0.42 
Ischemic heart 
disease 
66.5 
46.9 
(12.5) 
26.2 (0.9) - 48.4 0.16 
Data are reported as weighted mean (SE) with weights equal to sample size. SD is not reported if data from only 
one study is available. CPAP: constant continuous positive airway pressure; ASV: adaptive servo-ventilation; IC: 
inactive control; O2: nocturnal oxygen; BMI: body mass index; AHI: apnoea-hypopnoea index; LVEF: left 
ventricular ejection fraction. 
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Table 2: Pairwise and network meta-analysis 
 Treatment 
effect (SE) 
95% CI p value Cochran’s Q 
test 
(p value) 
I2 statistic Between-
study 
variance (τ2) 
CPAP vs control 
Pairwise 6.54 1.99 – 11.09 0.005 
17.9 
(p = 0.0005) 
83.2% 12.65 
Network 4.41 0.33 – 8.50 0.036   … 
ASV vs control 
Pairwise 2.87 -0.51 – 6.25 0.096 
27.8 
(p = 0.0001) 
78.4% 6.64 
Network 3.79 0.55 – 7.03 0.025   … 
O2 vs control 
Pairwise 1.7 -7.57 – 10.97 0.719    
Network 3.15 -3.91 – 10.20 0.353   … 
ASV vs CPAP 
Pairwise 2.04 -3.00 – 7.09 0.427 
61.8 (p < 
0.0001) 
96.8% 61.22 
Network -0.62 -4.84 – 3.60 0.755    
O2 vs ASV 
Pairwise 0.7 -8.26 – 9.66 0.878    
Network -0.64 -7.67 – 6.39 0.846    
Test for inconsistency in network meta-analysis: χ2 1.15 (11 df); p= 0.35 
CPAP: constant continuous positive airway pressure; ASV: adaptive servo-ventilation; O2: nocturnal oxygen. 
 
 
 
 
